- Home
- HLVX vs AVTX Comparison
HLVX vs AVTX Comparison
Compare HLVX & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLVX
- AVTX
- Stock Information
- Founded
- HLVX 2020
- AVTX 2011
- Country
- HLVX United States
- AVTX United States
- Employees
- HLVX N/A
- AVTX N/A
- Industry
- HLVX Biotechnology: Pharmaceutical Preparations
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- HLVX Health Care
- AVTX Health Care
- Exchange
- HLVX Nasdaq
- AVTX Nasdaq
- Market Cap
- HLVX 87.6M
- AVTX 90.9M
- IPO Year
- HLVX 2022
- AVTX 2015
- Fundamental
- Price
- HLVX $1.91
- AVTX $9.38
- Analyst Decision
- HLVX Hold
- AVTX Buy
- Analyst Count
- HLVX 5
- AVTX 3
- Target Price
- HLVX $2.33
- AVTX $29.50
- AVG Volume (30 Days)
- HLVX 245.3K
- AVTX 90.5K
- Earning Date
- HLVX 11-07-2024
- AVTX 11-07-2024
- Dividend Yield
- HLVX N/A
- AVTX N/A
- EPS Growth
- HLVX N/A
- AVTX N/A
- EPS
- HLVX N/A
- AVTX N/A
- Revenue
- HLVX N/A
- AVTX $820,000.00
- Revenue This Year
- HLVX N/A
- AVTX N/A
- Revenue Next Year
- HLVX N/A
- AVTX N/A
- P/E Ratio
- HLVX N/A
- AVTX N/A
- Revenue Growth
- HLVX N/A
- AVTX N/A
- 52 Week Low
- HLVX $1.55
- AVTX $3.95
- 52 Week High
- HLVX $20.22
- AVTX $34.46
- Technical
- Relative Strength Index (RSI)
- HLVX 47.67
- AVTX 42.72
- Support Level
- HLVX $1.88
- AVTX $9.00
- Resistance Level
- HLVX $2.13
- AVTX $9.82
- Average True Range (ATR)
- HLVX 0.07
- AVTX 0.75
- MACD
- HLVX -0.01
- AVTX 0.01
- Stochastic Oscillator
- HLVX 15.56
- AVTX 27.86
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).